Double minutes: exploring the formation and oncogenic roles in cancer progression

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Gene

• Publication date

  2025-11-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.gene.2025.149879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer

  2025cited by this paper
• Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies

  2025cited by this paper
• Molecular Crosstalk Between RUNX2 and HIF-1α in Osteosarcoma: Implications for Angiogenesis, Metastasis, and Therapy Resistance

  2025cited by this paper
• NF-κB signaling pathway in osteosarcoma: from signaling networks to targeted therapy

  2025cited by this paper
• MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damage

  2025cited by this paper
• Harnessing multi-omics to revolutionize understanding and management of osteosarcoma: A pathway to precision medicine (Review)

  2025cited by this paper
• Inhibition of key DNA double strand break repair protein kinases enhances radiosensitivity of head and neck cancer cells to X-ray and proton irradiation

  2024cited by this paper
• Tumor extrachromosomal DNA: Biogenesis and recent advances in the field.

  2024cited by this paper
• Dynamic genomic changes in methotrexate-resistant human cancer cell lines beyond DHFR amplification suggest potential new targets for preventing drug resistance

  2024cited by this paper
• Abstract 6599: 3D genomic analysis reveals novel enhancer hijacking mechanisms caused by complex structural alterations that drive oncogene overexpression

  2024cited by this paper
• Applications of Digital Polymerase Chain Reaction (dPCR) in Molecular and Clinical Testing.

  2024cited by this paper
• Decoding the Tumour Microenvironment: Molecular Players, Pathways, and Therapeutic Targets in Cancer Treatment

  2024cited by this paper
• Unveiling the mysteries of extrachromosomal circular DNA: from generation to clinical relevance in human cancers and health

  2024cited by this paper
• Deep learning method for detecting fluorescence spots in cancer diagnostics via fluorescence in situ hybridization

  2024cited by this paper
• The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma

  2024cited by this paper
• Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer

  2024cited by this paper
• An Inherited Allele Confers Prostate Cancer Progression and Drug Resistance via RFX6/HOXA10‐Orchestrated TGFβ Signaling

  2024cited by this paper
• Therapeutic Targeting of DNA Replication Stress in Cancer

  2023cited by this paper
• ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines

  2023cited by this paper
• Extrachromosomal DNA (ecDNA): Unveiling its role in cancer progression and implications for early detection

  2023cited by this paper
• MYC function and regulation in physiological perspective

  2023cited by this paper
• Novel insights into the ecDNA formation mechanism involving MSH3 in methotrexate-resistant human colorectal cancer cells

  2023cited by this paper
• CKM and TERT dual promoters drive CRISPR–dCas9 to specifically inhibit the malignant behavior of osteosarcoma cells

  2023cited by this paper
• Extrachromosomal DNA (ecDNA) in cancer: mechanisms, functions, and clinical implications

  2023cited by this paper
• Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors

  2023cited by this paper
• Histone Demethylase Modulation: Epigenetic Strategy to Combat Cancer Progression

  2023cited by this paper
• Emerging strategies for cancer therapy by ATR inhibitors

  2023cited by this paper
• The effects of MYC on tumor immunity and immunotherapy

  2023cited by this paper
• Epigenetic reprogramming in cancer: From diagnosis to treatment

  2023cited by this paper
• c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment

  2023cited by this paper
• The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy

  2023cited by this paper
• In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.

  2022cited by this paper
• Tumor hijacks macrophages and microbiota through extracellular vesicles

  2022cited by this paper
• Reductive damage induced autophagy inhibition for tumor therapy

  2022cited by this paper
• A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma

  2022cited by this paper
• Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma

  2022cited by this paper
• Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts

  2022cited by this paper
• Circular RNA Controls Tumor Occurrence and Development via Cell Cycle Regulation

  2022cited by this paper
• Extrachromosomal Circular DNAs, Amplified Oncogenes, and CRISPR-Cas9 System

  2022cited by this paper
• Inhibition of DNA Repair by Inappropriate Activation of ATM, PARP, and DNA-PK with the Drug Agonist AsiDNA

  2022cited by this paper
• Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches

  2022cited by this paper
• Pioneering insights of extrachromosomal DNA (ecDNA) generation, action and its implications for cancer therapy

  2022cited by this paper
• Life of double minutes: generation, maintenance, and elimination

  2022cited by this paper
• A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies

  2022cited by this paper
• Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development

  2022cited by this paper
• MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma

  2022cited by this paper
• Extrachromosomal circular DNA in cancer: history, current knowledge, and methods.

  2022cited by this paper
• DNA Damage Clustering after Ionizing Radiation and Consequences in the Processing of Chromatin Breaks

  2022cited by this paper
• CRISPR/Cas9 nanoeditor of double knockout large fragments of E6 and E7 oncogenes for reversing drugs resistance in cervical cancer

  2021cited by this paper
• Engineering large-scale chromosomal deletions by CRISPR-Cas9

  2021cited by this paper
• OUP accepted manuscript

  2021cited by this paper
• Chromothripsis followed by circular recombination drives oncogene amplification in human cancer

  2021cited by this paper
• ecDNA hubs drive cooperative intermolecular oncogene expression

  2021cited by this paper
• CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer

  2021cited by this paper
• Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia adenocarcinoma

  2021cited by this paper
• Extrachromosomal DNA: An Emerging Hallmark in Human Cancer.

  2021cited by this paper
• Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way

  2021cited by this paper
• Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing

  2021cited by this paper
• A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia

  2021cited by this paper
• Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment

  2021cited by this paper
• Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?

  2021cited by this paper
• Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer

  2020cited by this paper
• Double‐strand breakage in the extrachromosomal double minutes triggers their aggregation in the nucleus, micronucleation, and morphological transformation

  2020cited by this paper
• Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

  2020cited by this paper
• Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting

  2020cited by this paper
• Beyond DNA-targeting in Cancer Chemotherapy. Emerging Frontiers- A Review.

  2020cited by this paper
• Adenoviral Vectors Armed with PAPILLOMAVIRUs Oncogene Specific CRISPR/Cas9 Kill Human-Papillomavirus-Induced Cervical Cancer Cells

  2020cited by this paper
• Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study

  2020cited by this paper
• The Determinant of DNA Repair Pathway Choices in Ionising Radiation-Induced DNA Double-Strand Breaks

  2020cited by this paper
• In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

  2020cited by this paper
• Molecular structure and evolution mechanism of two populations of double minutes in human colorectal cancer cells

  2020cited by this paper
• Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy.

  2020cited by this paper
• Decitabine Induces Gene Derepression on Monosomic Chromosomes: In Vitro and In Vivo Effects in Adverse-Risk Cytogenetics AML

  2020cited by this paper
• Chromothripsis drives the evolution of gene amplification in cancer

  2020cited by this paper
• A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.

  2020cited by this paper
• Extrachromosomal oncogene amplification in tumour pathogenesis and evolution

  2019cited by this paper
• Functional Enhancers Shape Extrachromosomal Oncogene Amplifications.

  2019cited by this paper
• Circular ecDNA promotes accessible chromatin and high oncogene expression

  2019cited by this paper
• The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors

  2019cited by this paper
• Cytogenomic characterization of double minute heterogeneity in therapy related acute myeloid leukemia.

  2019cited by this paper
• Exploring the landscape of focal amplifications in cancer using AmpliconArchitect

  2019cited by this paper
• Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma

  2019cited by this paper
• Generation and maintenance of acentric stable double minutes from chromosome arms in inter-species hybrid cells

  2019cited by this paper
• Structure and evolution of double minutes in diagnosis and relapse brain tumors

  2018cited by this paper
• MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences

  2018cited by this paper
• Mechanisms of receptor tyrosine kinase activation in cancer

  2018cited by this paper
• Inhibiting homologous recombination decreases extrachromosomal amplification but has no effect on intrachromosomal amplification in methotrexate‐resistant colon cancer cells

  2018cited by this paper
• Extrachromosomal oncogene amplification drives tumor evolution and genetic heterogeneity

  2017cited by this paper
• Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment

  2017cited by this paper
• BET inhibitors: a novel epigenetic approach

  2017cited by this paper
• Marked for death: targeting epigenetic changes in cancer

  2017cited by this paper
• The challenges of tumor genetic diversity

  2017cited by this paper
• Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype.

  2016cited by this paper
• CHROMOTHRIPSIS FROM DNA DAMAGE IN MICRONUCLEI

  2015cited by this paper
• Association between sister chromatid exchange and double minute chromosomes in human tumor cells

  2015cited by this paper
• Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways

  2015cited by this paper
• Constitutive ERK1/2 activation contributes to production of double minute chromosomes in tumour cells

  2014cited by this paper
• Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer

  2014cited by this paper
• Novel role for non-homologous end joining in the formation of double minutes in methotrexate-resistant colon cancer cells

  2014cited by this paper
• Extrachromosomal driver mutations in glioblastoma and low grade glioma

  2014cited by this paper

• No citing papers are available for this paper.